Cancer Drugs Extend Mouse Lifespan 30% | Anti-Aging Potential
- A new study indicates that a combination of two cancer drugs, trametinib and rapamycin, can significantly increase lifespan in mice.
- The study, published in Nature Aging, also noted that the drug combination reduced chronic inflammation and delayed cancer growth in the aging mice.
- Linda Partridge, a geneticist at University College London and the Max Planck Institute for Biology of ageing, said the drugs are good candidates for human trials to explore...
Groundbreaking research reveals that a combination of the cancer drugs trametinib and rapamycin extended the lifespan of mice by an impressive 30%. This study, featured in Nature Aging, demonstrates the potential of these FDA-approved drugs to combat aging by reducing chronic inflammation and delaying cancer development. While results in mice do not guarantee similar outcomes for humans, the findings provide a compelling case for future human trials. The drugs target cellular pathways critical to aging and disease, hinting at the possibility of extending healthy lifespans. News Directory 3 is here to bring you the latest in scientific breakthroughs. With both drugs already in use, the stage is set for exploring their potential as geroprotectors, offering hope for healthier aging.Discover what’s next in the fight against aging.
Cancer Therapy Drug Combo Extends Lifespan in Mice
A new study indicates that a combination of two cancer drugs, trametinib and rapamycin, can significantly increase lifespan in mice. Researchers observed lifespan extensions of up to 30% when the drugs were administered together.
The study, published in Nature Aging, also noted that the drug combination reduced chronic inflammation and delayed cancer growth in the aging mice. While the findings are promising, researchers caution that results in mice do not automatically translate to humans.
Linda Partridge, a geneticist at University College London and the Max Planck Institute for Biology of ageing, said the drugs are good candidates for human trials to explore ways to help older people age better. Both trametinib and rapamycin are already approved by the U.S. Food and Drug Administration (FDA).
The drugs target cell dialog pathways vital in aging and disease development. Rapamycin inhibits mTOR, a protein regulating cell division and death, while trametinib disrupts the RAS/Mek/Erk pathway, also involved in cancerous cell proliferation. The study highlights the potential of these FDA-approved drugs as a cancer therapy.
“While we do not expect a similar extension to human lifespans as we found in mice, we hope that the drugs we’re investigating could help people to stay healthy and disease-free for longer late in life,” partridge said.
Individually, rapamycin extended lifespan by 15% to 20%, and trametinib by 5% to 10%. The combined treatment yielded even greater results, increasing lifespan by up to 29%. Tissue samples showed that the drug cocktail influenced gene activity differently than either drug alone.
What’s next
Researchers plan to optimize the use of trametinib to maximize its benefits while minimizing side effects. Sebastian Grönke,a senior postdoctoral researcher at the Max Planck Institute for Biology of Ageing,said trametinib,especially combined with rapamycin,is a good candidate for clinical trials as a geroprotector.